A Study of TPX-0005 (Repotrectinib) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Turning Point Therapeutics is enrolling patients in a Phase 1/2 trial called TRIDENT-1. The multi-center trial is evaluating our lead drug candidate, repotrectinib, for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) as well as patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
Tumors with mutations to their ROS1, NTRK and ALK genes have a higher likelihood of developing resistance to existing targeted therapies. In many cases, these mutations prevent existing medicine from targeting and binding to the tumor as effectively as tumors that don’t carry the mutations. Repotrectinib is designed to be smaller and less bulky than existing targeted therapies, and may circumvent some the resistance mechanisms found in tumors with ROS1, NTRK and ALK mutations.
Repotrectinib is being assessed for safety, tolerability, pharmacokinetics and antitumor activity.
*For a complete list of inclusion and exclusion criteria, visit www.clinicaltrials.gov